Global Antiviral Immunoglobulin Market Snapshot

The global antiviral immunoglobulin market was valued at US$ 4.6 Billion in 2022 and is expected to reach US$ 10.9 Billion by 2033. By route of administration, the IV segment is projected to continue its growth momentum over the forecast period (2023 to 2033) with an anticipated compound annual growth rate (CAGR) of close to 7.4%. This growth is driven by factors such as the increasing prevalence of viral infections, expanding healthcare infrastructure, and advancements in IV administration techniques.

Market Outlook:

Data Points Market Insights
Market Value 2022 US$ 4.6 Billion
Market Value 2023 US$ 5.0 Billion
Market Value 2033 US$ 10.9 Billion
CAGR 2023 to 2033 8.2%
Market Share of Top 5 Countries 63.1%
Key Market Players Biotest AG, Baxter International Inc., Octapharma AG, LFB Biotechnologies, Grifols SA, CSL Behring, China Biologics Products Inc., Kedrion Biopharma, BDI Pharma Inc., Bayers, Baxalta Incorporated, Kedrion SPA, AstraZeneca PLC., Omrix Biopharma, Sanofi, Cangene corporation.

Immunoglobulins have traditionally assisted in opsonization, bacteriolysis stimulation, and toxin neutralization in bacterial infections. In viral infections, immunoglobulins prevent the infection of uninfected cells, support antibody-directed cell-mediated cytotoxicity by natural killer cells, and neutralize viruses either alone or in conjunction with complement. They offer a rapid, safe, and cost-effective approach to obtaining valuable information about an individual's health status.

Due to the global increase in immunosuppression caused by conditions such as AIDS, organ transplantation, tumors, autoimmune diseases, and the emergence of multidrug-resistant organisms, there is a renewed interest in the use of antibody preparations for preventing infections in high-risk populations. Substantial research has demonstrated that therapies aiming to promote or enhance the immune response may be feasible and beneficial for immunocompromised individuals.

Overall, immunoglobulins play a crucial role in various aspects of immune defense, providing targeted protection against pathogens and contributing to the well-being of individuals, particularly those with compromised immune systems.

Don't pay for what you don't need

Customize your report by selecting specific countries or regions and save 30%!

Sales Analysis of Antiviral Immunoglobulin Market from 2012 to 2022 Vs Market Outlook for 2023 to 2033

The global market recorded a historic CAGR of 6.8% in the last 10 years from 2012 – 2022. The global antiviral immunoglobulins was around 4.7% of the overall US$ 97.14 Billion of the global antivirals market in 2022. The increasing prevalence of viral infections globally, including diseases such as HIV, hepatitis, and influenza, is a major driver for the antiviral immunoglobulin market. These infections impose a significant healthcare burden, necessitating a greater demand for antiviral treatments, including immunoglobulins. As viral infections continue to impact populations worldwide, the need for effective antiviral therapies such as immunoglobulins is on the rise, driving the growth of the market.

According to the data published by CDC in 2021, 36,136 people received an HIV diagnosis in the United States and dependent areas. The annual number of new diagnoses decreased by 7% from 2017 to 2021.

The use of immunoglobulins provides targeted and specific immune responses against viral pathogens, making them essential in combating viral infections and managing their associated complications.

Improvements in healthcare infrastructure, particularly in developing countries, have led to better access to antiviral immunoglobulin therapies. This expansion of healthcare facilities, along with increasing affordability and availability of antiviral immunoglobulins, contributes to market growth.

What are the Key Opportunities for the Antiviral Immunoglobulin Manufacturers?

Viral outbreaks, such as influenza or emerging infectious diseases like COVID-19, lead to a surge in demand for antiviral immunoglobulin products. Synthetic biology offers a solution to the challenges associated with traditional antibody generation methods. A study conducted by Aaron Sato and published on February 5, 2020, highlighted how synthetic biology can address these issues, potentially leading to the development of novel medications through optimized antibodies.

Collaborative efforts in research, development, and commercialization can expand the market reach of antiviral immunoglobulin products and facilitate the exploration of new applications. Improved healthcare access in developing countries presents an opportunity for market expansion, as these regions often face a higher burden of viral infections and have a growing middle-class population with increased healthcare spending capacity.

The overall economic growth of a country or region significantly influences the demand for antiviral immunoglobulin products. During periods of economic growth, healthcare spending tends to increase, driving the demand for antiviral treatments.

Sabyasachi Ghosh
Sabyasachi Ghosh

Principal Consultant

Talk to Analyst

Find your sweet spots for generating winning opportunities in this market.

What are the Factors Restraining the Demand for the Antiviral Immunoglobulin?

Strict regulatory requirements, encompassing safety and efficacy evaluations, pose significant challenges to the development and commercialization of antiviral immunoglobulin products. The rigorous process of meeting these regulatory standards can be time-consuming and expensive, creating barriers to market entry and potentially restraining the demand for these products. Compliance with regulatory guidelines ensures the safety and effectiveness of immunoglobulin therapies but can also prolong the product development timeline and increase costs. These factors can impact the accessibility, affordability, and availability of antiviral immunoglobulin treatments, thus limiting their demand in the market.

In some cases, there may be alternative treatments available for viral infections, such as antiviral medications or vaccines. These alternatives may offer convenience, cost-effectiveness, or targeted therapeutic benefits, leading to reduced demand for antiviral immunoglobulin therapies.

Country-wise Insights

Why is the U.S. a Prominent Market for Antiviral Immunoglobulin in the North American region?

In the year 2022, the U.S. holds a dominant share of 88.7% in the North American market, and it is expected to grow at a CAGR of 8.4% during the forecasted years. The U.S. is known for having one of the highest healthcare costs globally. However, this also facilitates widespread access and affordability for advanced medical therapies, including antiviral immunoglobulins. The increasing cost of healthcare drives the demand for innovative and effective treatments, thus expanding the market for antiviral immunoglobulin products.

The healthcare insurance system in the U.S. is complex, involving various commercial and governmental insurance companies. Fortunately, antiviral immunoglobulin therapy is often covered by these insurance policies, which improves patients' access to and affordability of these treatments. The coverage provided by insurance companies eases the financial burden on patients, ensuring they can benefit from antiviral immunoglobulin therapies.

What Makes China a Large Market for Antiviral Immunoglobulin?

In 2022, China emerged as the dominant player in the East Asia market, contributing around US$ 198.3 million. With the world's largest population, China faces a significant disease burden, leading to an increased demand for medical supplies, including antiviral immunoglobulins. This presents a lucrative market opportunity for manufacturers and sellers of these products, given the substantial patient pool in the country.

In May 2023, a prominent health expert in China predicted a potential surge of 65 million weekly COVID-19 cases in the country by June. This surge is fuelled by the XBB strain, a respiratory disease that has been spreading in China for nearly six months. With the virus still circulating and public immunity waning, there remains a possibility of the emergence of a new, more dangerous sub-variant. This ongoing situation further underscores the need for effective medical interventions such as antiviral immunoglobulins to address the challenges posed by the evolving viral landscape in China.

What Makes Japan a Highly Lucrative Market for Antiviral Immunoglobulin?

In 2022, Japan held a significant market share of around 57.3% in the East Asia market. Japan boasts highly skilled and well-trained healthcare professionals, including doctors, researchers, and technicians. Additionally, Japan has one of the highest proportions of elderly individuals globally. This demographic factor necessitates the use of antiviral immunoglobulins to treat or prevent viral infections in older populations.

The aging population in Japan has resulted in an increased demand for healthcare products, including antiviral immunoglobulins, to cater to their specific medical needs. The Japanese population benefits from a well-developed and established healthcare system that provides exceptional medical care. This advanced healthcare system creates an environment conducive to the production and utilization of antiviral immunoglobulin products, ensuring their accessibility and effectiveness in addressing the healthcare needs of the Japanese population.

Get the data you need at a Fraction of the cost

Personalize your report by choosing insights you need
and save 40%!

Category-wise Insights

Why Intravenous Route of Administration is preferred majorly in Antiviral Immunoglobulin?

The intravenous route of administration accounted for a significant market share of 52.3% in the global market in 2022. When administered intravenously, antiviral immunoglobulins can be rapidly and directly delivered into the bloodstream. This route of administration offers enhanced bioavailability and a prompt response against infections compared to other methods such as oral or subcutaneous administration.

By delivering antiviral immunoglobulins intravenously, the effective targeting of the medication to the desired location is ensured, leading to improved efficacy and treatment outcomes. Intravenous administration allows healthcare professionals to precisely control the delivery of antiviral immunoglobulins to the patient. They can accurately measure and adjust the dosage based on the individual patient's needs. This dose consistency contributes to optimal therapeutic results while minimizing the risk of under or overdosing.

Which Distribution Channel is Benefiting the Global Market?

Hospital pharmacies play a significant role in the antiviral immunoglobulin market, representing 42.5% of end users in 2022 and exhibiting a CAGR of 9.8% over the forecast period. Hospitals are often the primary healthcare facility patients turn to when they contract a viral illness. In the hospital setting, intravenous administration of antiviral immunoglobulin is commonly employed for the treatment of patients with severe viral infections. This ensures close monitoring by medical staff and allows for prompt adjustments to the treatment plan based on the patient's response. Hospitals possess the necessary infrastructure and expertise to administer these drugs intravenously, ensuring the safe and effective delivery of antiviral immunoglobulins to patients.

Competitive Landscape

The population may become less in need of antiviral treatments due to population immunity brought on by high vaccination rates and prior diseases.

  • In February 2022, the FDA approved Bebtelovimab, a novel antibody medication developed by AbCellera and Eli Lilly, for the treatment of the Omicron variant of COVID-19. The FDA's approval signifies the recognition of Bebtelovimab's efficacy and safety profile, offering healthcare professionals a valuable tool in managing and treating COVID-19 cases, particularly those at higher risk of severe illness.
  • In April 2023, SAB Biotherapeutics' SAB-176 received fast-track designation from the FDA. This designation was granted to expedite the development and review process of SAB-176, a potential treatment for Type A and Type B influenza.
  • By 2022, it is anticipated that Western pharmaceutical companies including AstraZeneca Plc. (AZN.L), BioNTech SE (22UAy.DE), Gilead Sciences Inc. (GILD.O), Merck & Co. (MRK.N), Moderna Inc. (MRNA.O), and Pfizer Inc. (PFE.N) will have earned nearly $100 billion from COVID vaccines and therapies.
  • By 2022, Western pharmaceutical companies, including AstraZeneca Plc., BioNTech SE, Gilead Sciences Inc., Merck & Co., Moderna Inc., and Pfizer Inc. have generated revenue of nearly $100 billion from COVID vaccines and therapies. The substantial earnings generated reflect the high demand for COVID vaccines and therapies, highlighting the global scale of the market and the financial success of these pharmaceutical companies in addressing the ongoing public health crisis.

With technological advances in the pharmaceutical sector, Antiviral Immunoglobulin will be useful in countering viral infections.

Similarly, recent developments related to the company’s active in the antiviral immunoglobulin market have been tracked by the team at Future Market Insights, which are available in the full report.

Report Scope as Per Antiviral Immunoglobulin Industry Analysis

Attribute Details
Forecast Period 2023 to 2033
Historical Data Available for 2012 to 2022
Market Analysis US$ Million for Value, Units for Volume
Key Regions Covered North America, Latin America, Europe, East Asia, South Asia, Oceania, Middle East, and Africa (MEA)
Key Countries Covered U.S., Canada, Brazil, Mexico, Argentina, Germany, Italy, France, U.K., Spain, BENELUX, Russia, India, Thailand, China, Indonesia, Malaysia, Japan, South Korea, Australia, New Zealand, GCC countries, Northern Africa and South Africa.
Key Market Segments Covered Route of Administration, Distribution Channel, and Region
Key Companies Profiled
  • Biotest AG
  • Baxter International Inc.
  • Octapharma AG
  • LFB Biotechnologies
  • Grifols SA
  • CSL Behring
  • China Biologics Products Inc.
  • Kedrion Biopharma
  • BDI Pharma Inc.
  • Bayers
  • Baxalta Incorporated
  • Kedrion SPA
  • AstraZeneca PLC.
  • Omrix Biopharma.
  • Sanofi
  • Cangene corporation
Report Coverage
  • Market Forecast, Competition Intelligence, DROT Analysis, Market Dynamics and Challenges, Strategic Growth Initiatives
Pricing Available upon Request

Key Market Segments Covered in the Antiviral Immunoglobulin Industry Research

By Route of Administration:

  • Intravenous
  • Subcutaneous
  • Intramuscular Injections

By Distribution Channel:

  • Hospital Pharmacies
  • Retail Pharmacies
  • Drug Store

By Region:

  • North America
  • Latin America
  • Europe
  • South Asia
  • East Asia
  • Oceania
  • MEA

Frequently Asked Questions

What is the market size in 2023?

The market is valued at US$ 5 billion in 2023.

How is the historical performance of the market?

From 2012 to 2022, the market registered a CAGR of 6.8%.

What will be the market value in 2033?

The market shall reach US$ 10.9 billion in 2033.

What is the CAGR from 2023 to 2033?

The market’s CAGR from 2023 to 2033 will be 7.4%.

What was North America's market revenue in 2022?

In 2022, the U.S. held a share of 88.7% of the North American market.

Table of Content

1. Executive Summary

    1.1. Global Market Outlook

    1.2. Demand Side Trends

    1.3. Supply-Side Trends

    1.4. Analysis and Recommendations

2. Market Overview

    2.1. Market Coverage / Taxonomy

    2.2. Market Definition / Scope / Limitations

    2.3. Inclusions and Exclusions

3. Key Market Trends

    3.1. Key Trends Impacting the Market

    3.2. Product Innovation / Development Trends

4. Value-Added Insights

    4.1. Product Adoption and Usage Analysis-By Region

    4.2. Product Vs Application Matrix, By Brands

    4.3. Regulatory Landscape, By Country

    4.4. Reimbursement Scenario, By Country

    4.5. Porter’s Analysis

    4.6. PESTLE Analysis

    4.7. Value Chain Analysis

    4.8. Patient Unmet Needs for Treatment

5. Market Background

    5.1. Macro-Economic Factors

        5.1.1. Global Healthcare Expenditure Outlook

        5.1.2. Global Life Science Market Outlook

        5.1.3. Global Immunoglobulin Market Outlook (Parent Market Outlook)

    5.2. Forecast Factors - Relevance & Impact

        5.2.1. Rising Prevalence of Immunodeficiency Diseases

        5.2.2. Technological Advancements in Manufacturing

        5.2.3. The emergence of new and re-emerging infectious diseases, such as Ebola, Zika, and COVID-19

        5.2.4. Improvements in healthcare infrastructure in developing countries

        5.2.5. Government Initiatives and Funding

        5.2.6. Increased awareness about viral infections and their potential complications

        5.2.7. The rising incidence of viral infections worldwide

        5.2.8. Cost of Treatment

    5.3. Market Dynamics

        5.3.1. Drivers

        5.3.2. Restraints

        5.3.3. Opportunity Analysis

6. Global Market Demand Volume (Units) Analysis 2012 to 2022 and Forecast, 2023 to 2033

    6.1. Historical Market Volume (Unit) Analysis, 2012 to 2022

    6.2. Current and Future Market Volume (Units) Analysis and Forecast Projections, 2023 to 2033

        6.2.1. Y-o-Y Growth Trend Analysis

7. Global Market – Pricing Analysis

    7.1. Regional Pricing Analysis By Antiviral Immunoglobulin

    7.2. Global Average Pricing Analysis Benchmark

    7.3. Pricing Assumptions

8. Global Market Demand (in Value or Size in US$ Million) Analysis 2012 to 2022 and Forecast, 2023 to 2033

    8.1. Historical Market Value (US$ Million) Analysis, 2012 to 2022

    8.2. Current and Future Market Size (US$ Million) Analysis and Forecast Projections, 2023 to 2033

        8.2.1. Y-o-Y Growth Trend Analysis

        8.2.2. Absolute $ Opportunity Analysis

9. Global Market Analysis 2012 to 2022 and Forecast 2023 to 2033, By Route of Administration 

    9.1. Introduction / Key Findings

    9.2. Historical Market Size (US$ Million) Analysis By Route of Administration, 2012 to 2022

    9.3. Current and Future Market Size (US$ Million) Analysis and Forecast By Route of Administration, 2023 to 2033

        9.3.1. Intravenous

        9.3.2. Subcutaneous

        9.3.3. Intramuscular Injections

    9.4. Market Attractiveness Analysis By Route of Administration

10. Global Market Analysis 2012 to 2022 and Forecast 2023 to 2033, By Distribution Channel

    10.1. Introduction / Key Findings

    10.2. Historical Market Size (US$ Million) Analysis By Distribution Channel, 2012 to 2022

    10.3. Current and Future Market Size (US$ Million) Analysis and Forecast By Distribution Channel, 2023 to 2033

        10.3.1. Hospital Pharmacies

        10.3.2. Retail Pharmacies

        10.3.3. Drug Stores

    10.4. Market Attractiveness Analysis By Distribution Channel

11. Global Market Analysis 2012 to 2022 and Forecast 2023 to 2033, by Region

    11.1. Introduction / Key Findings

    11.2. Historical Market Size (US$ Million) Analysis, By Region, 2012 to 2022

    11.3. Current and Future Market Size (US$ Million) Analysis and Forecast By Region, 2023 to 2033

        11.3.1. North America

        11.3.2. Latin America

        11.3.3. Europe

        11.3.4. South Asia

        11.3.5. East Asia

        11.3.6. Oceania

        11.3.7. Middle East and Africa

    11.4. Market Attractiveness Analysis By Region

12. North America Market Analysis 2012 to 2022 and Forecast 2023 to 2033

    12.1. Introduction / Key Findings

    12.2. Historical Market Size (US$ Million) Analysis By Market Taxonomy, 2012 to 2022

    12.3. Current and Future Market Size (US$ Million) Analysis and Forecast By Market Taxonomy, 2023 to 2033

        12.3.1. By Country

            12.3.1.1. U.S.

            12.3.1.2. Canada

        12.3.2. By Route of Administration

        12.3.3. By Distribution Channel

    12.4. Market Attractiveness Analysis By Region

        12.4.1. By Country

        12.4.2. By Route of Administration

        12.4.3. By Distribution Channel

    12.5. Market trends

    12.6. Key Market Participants - Intensity Mapping

    12.7. Drivers and Restraints - Impact Analysis

    12.8. Country Level Analysis & Forecast

        12.8.1. U.S. Market Analysis

            12.8.1.1. Introduction

            12.8.1.2. Market Analysis and Forecast by Market Taxonomy

                12.8.1.2.1. By Route of Administration

                12.8.1.2.2. By Distribution Channel

        12.8.2. Canada Market Analysis

            12.8.2.1. Introduction

            12.8.2.2. Market Analysis and Forecast by Market Taxonomy

                12.8.2.2.1. By Route of Administration

                12.8.2.2.2. By Distribution Channel

13. Latin America Market Analysis 2012 to 2022 and Forecast 2023 to 2033

    13.1. Introduction / Key Findings

    13.2. Historical Market Size (US$ Million) Analysis By Market Taxonomy, 2012 to 2022

    13.3. Current and Future Market Size (US$ Million) Analysis and Forecast By Market Taxonomy, 2023 to 2033

        13.3.1. By Country

            13.3.1.1. Brazil

            13.3.1.2. Mexico

            13.3.1.3. Argentina

            13.3.1.4. Rest of Latin America

        13.3.2. By Route of Administration

        13.3.3. By Distribution Channel

    13.4. Market Attractiveness Analysis By Region

        13.4.1. By Country

        13.4.2. By Route of Administration

        13.4.3. By Distribution Channel

    13.5. Market trends

    13.6. Key Market Participants - Intensity Mapping

    13.7. Drivers and Restraints - Impact Analysis

    13.8. Country Level Analysis & Forecast

        13.8.1. Brazil Market Analysis

            13.8.1.1. Introduction

            13.8.1.2. Market Analysis and Forecast by Market Taxonomy

                13.8.1.2.1. By Route of Administration

                13.8.1.2.2. By Distribution Channel

        13.8.2. Mexico Market Analysis

            13.8.2.1. Introduction

            13.8.2.2. Market Analysis and Forecast by Market Taxonomy

                13.8.2.2.1. By Route of Administration

                13.8.2.2.2. By Distribution Channel

        13.8.3. Argentina Market Analysis

            13.8.3.1. Introduction

            13.8.3.2. Market Analysis and Forecast by Market Taxonomy

                13.8.3.2.1. By Route of Administration

                13.8.3.2.2. By Distribution Channel

14. Europe Market Analysis 2012 to 2022 and Forecast 2023 to 2033

    14.1. Introduction / Key Findings

    14.2. Historical Market Size (US$ Million) Analysis By Market Taxonomy, 2012 to 2022

    14.3. Current and Future Market Size (US$ Million) Analysis and Forecast By Market Taxonomy, 2023 to 2033

        14.3.1. By Country 

            14.3.1.1. Germany

            14.3.1.2. France

            14.3.1.3. Spain

            14.3.1.4. Italy

            14.3.1.5. Russia

            14.3.1.6. BENELUX

            14.3.1.7. United Kingdom

            14.3.1.8. Rest of Europe

        14.3.2. By Route of Administration

        14.3.3. By Distribution Channel

    14.4. Market Attractiveness Analysis By Region

        14.4.1. By Country

        14.4.2. By Route of Administration

        14.4.3. By Distribution Channel

    14.5. Market trends

    14.6. Key Market Participants - Intensity Mapping

    14.7. Drivers and Restraints - Impact Analysis

    14.8. Country Level Analysis & Forecast

        14.8.1. Germany Market Analysis

            14.8.1.1. Introduction

            14.8.1.2. Market Analysis and Forecast by Market Taxonomy

                14.8.1.2.1. By Route of Administration

                14.8.1.2.2. By Distribution Channel

        14.8.2. France Market Analysis

            14.8.2.1. Introduction

            14.8.2.2. Market Analysis and Forecast by Market Taxonomy

                14.8.2.2.1. By Route of Administration

                14.8.2.2.2. By Distribution Channel

        14.8.3. Spain Market Analysis

            14.8.3.1. Introduction

            14.8.3.2. Market Analysis and Forecast by Market Taxonomy

                14.8.3.2.1. By Route of Administration

                14.8.3.2.2. By Distribution Channel

        14.8.4. Russia Market Analysis

            14.8.4.1. Introduction

            14.8.4.2. Market Analysis and Forecast by Market Taxonomy

                14.8.4.2.1. By Route of Administration

                14.8.4.2.2. By Distribution Channel

        14.8.5. Italy Market Analysis

            14.8.5.1. Introduction

            14.8.5.2. Market Analysis and Forecast by Market Taxonomy

                14.8.5.2.1. By Route of Administration

                14.8.5.2.2. By Distribution Channel

        14.8.6. BENELUX Market Analysis

            14.8.6.1. Introduction

            14.8.6.2. Market Analysis and Forecast by Market Taxonomy

                14.8.6.2.1. By Route of Administration

                14.8.6.2.2. By Distribution Channel

        14.8.7. United Kingdom Market Analysis

            14.8.7.1. Introduction

            14.8.7.2. Market Analysis and Forecast by Market Taxonomy

                14.8.7.2.1. By Route of Administration

                14.8.7.2.2. By Distribution Channel

15. South Asia Market Analysis 2012 to 2022 and Forecast 2023 to 2033

    15.1. Introduction / Key Findings

    15.2. Historical Market Size (US$ Million) Analysis By Market Taxonomy, 2012 to 2022

    15.3. Current and Future Market Size (US$ Million) Analysis and Forecast By Market Taxonomy, 2023 to 2033

        15.3.1. By Country 

            15.3.1.1. India

            15.3.1.2. Indonesia

            15.3.1.3. Thailand

            15.3.1.4. Malaysia

            15.3.1.5. Rest of South Africa

        15.3.2. By Route of Administration

        15.3.3. By Distribution Channel

    15.4. Market Attractiveness Analysis By Region

        15.4.1. By Country

        15.4.2. By Route of Administration

        15.4.3. By Distribution Channel

    15.5. Market trends

    15.6. Key Market Participants - Intensity Mapping

    15.7. Drivers and Restraints - Impact Analysis

    15.8. Country Level Analysis & Forecast

        15.8.1. India Market Analysis

            15.8.1.1. Introduction

            15.8.1.2. Market Analysis and Forecast by Market Taxonomy

                15.8.1.2.1. By Route of Administration

                15.8.1.2.2. By Distribution Channel

        15.8.2. Indonesia Market Analysis

            15.8.2.1. Introduction

            15.8.2.2. Market Analysis and Forecast by Market Taxonomy

                15.8.2.2.1. By Route of Administration

                15.8.2.2.2. By Distribution Channel

        15.8.3. Thailand Market Analysis

            15.8.3.1. Introduction

            15.8.3.2. Market Analysis and Forecast by Market Taxonomy

                15.8.3.2.1. By Route of Administration

                15.8.3.2.2. By Distribution Channel

        15.8.4. Malaysia Market Analysis

            15.8.4.1. Introduction

            15.8.4.2. Market Analysis and Forecast by Market Taxonomy

                15.8.4.2.1. By Route of Administration

                15.8.4.2.2. By Distribution Channel

16. East Asia Market Analysis 2012 to 2022 and Forecast 2023 to 2033

    16.1. Introduction / Key Findings

    16.2. Historical Market Size (US$ Million) Analysis By Market Taxonomy, 2012 to 2022

    16.3. Current and Future Market Size (US$ Million) Analysis and Forecast By Market Taxonomy, 2023 to 2033

        16.3.1. By Country 

            16.3.1.1. China

            16.3.1.2. Japan

            16.3.1.3. South Korea

        16.3.2. By Route of Administration

        16.3.3. By Distribution Channel

    16.4. Market Attractiveness Analysis By Region

        16.4.1. By Country

        16.4.2. By Route of Administration

        16.4.3. By Distribution Channel

    16.5. Market trends

    16.6. Key Market Participants - Intensity Mapping

    16.7. Drivers and Restraints - Impact Analysis

    16.8. Country Level Analysis & Forecast

        16.8.1. China Market Analysis

            16.8.1.1. Introduction

            16.8.1.2. Market Analysis and Forecast by Market Taxonomy

                16.8.1.2.1. By Route of Administration

                16.8.1.2.2. By Distribution Channel

        16.8.2. Japan Market Analysis

            16.8.2.1. Introduction

            16.8.2.2. Market Analysis and Forecast by Market Taxonomy

                16.8.2.2.1. By Route of Administration

                16.8.2.2.2. By Distribution Channel

        16.8.3. South Korea Market Analysis

            16.8.3.1. Introduction

            16.8.3.2. Market Analysis and Forecast by Market Taxonomy

                16.8.3.2.1. By Route of Administration

                16.8.3.2.2. By Distribution Channel

17. Oceania Market Analysis 2012 to 2022 and Forecast 2023 to 2033

    17.1. Introduction / Key Findings

    17.2. Historical Market Size (US$ Million) Analysis By Market Taxonomy, 2012 to 2022

    17.3. Current and Future Market Size (US$ Million) Analysis and Forecast By Market Taxonomy, 2023 to 2033

        17.3.1. By Country 

            17.3.1.1. Australia

            17.3.1.2. New Zealand

        17.3.2. By Route of Administration

        17.3.3. By Distribution Channel

    17.4. Market Attractiveness Analysis By Region

        17.4.1. By Country

        17.4.2. By Route of Administration

        17.4.3. By Distribution Channel

    17.5. Market trends

    17.6. Key Market Participants - Intensity Mapping

    17.7. Drivers and Restraints - Impact Analysis

    17.8. Country Level Analysis & Forecast

        17.8.1. Australia Market Analysis

            17.8.1.1. Introduction

            17.8.1.2. Market Analysis and Forecast by Market Taxonomy

                17.8.1.2.1. By Route of Administration

                17.8.1.2.2. By Distribution Channel

        17.8.2. New Zealand Market Analysis

            17.8.2.1. Introduction

            17.8.2.2. Market Analysis and Forecast by Market Taxonomy

                17.8.2.2.1. By Route of Administration

                17.8.2.2.2. By Distribution Channel

18. Middle East and Africa Market Analysis 2012 to 2022 and Forecast 2023 to 2033

    18.1. Introduction / Key Findings

    18.2. Historical Market Size (US$ Million) Analysis By Market Taxonomy, 2012 to 2022

    18.3. Current and Future Market Size (US$ Million) Analysis and Forecast By Market Taxonomy, 2023 to 2033

        18.3.1. By Country 

            18.3.1.1. GCC Countries

            18.3.1.2. Türkiye

            18.3.1.3. South Africa

            18.3.1.4. Northern Africa

            18.3.1.5. Rest of Middle East and Africa

        18.3.2. By Route of Administration

        18.3.3. By Distribution Channel

    18.4. Market Attractiveness Analysis By Region

        18.4.1. By Country

        18.4.2. By Route of Administration

        18.4.3. By Distribution Channel

    18.5. Market trends

    18.6. Key Market Participants - Intensity Mapping

    18.7. Drivers and Restraints - Impact Analysis

    18.8. Country Level Analysis & Forecast

        18.8.1. GCC Countries Market Analysis

            18.8.1.1. Introduction

            18.8.1.2. Market Analysis and Forecast by Market Taxonomy

                18.8.1.2.1. By Route of Administration

                18.8.1.2.2. By Distribution Channel

        18.8.2. Türkiye Market Analysis

            18.8.2.1. Introduction

            18.8.2.2. Market Analysis and Forecast by Market Taxonomy

                18.8.2.2.1. By Route of Administration

                18.8.2.2.2. By Distribution Channel

        18.8.3. South Africa Market Analysis

            18.8.3.1. Introduction

            18.8.3.2. Market Analysis and Forecast by Market Taxonomy

                18.8.3.2.1. By Route of Administration

                18.8.3.2.2. By Distribution Channel

        18.8.4. Northern Africa Market Analysis

            18.8.4.1. Introduction

            18.8.4.2. Market Analysis and Forecast by Market Taxonomy

                18.8.4.2.1. By Route of Administration

                18.8.4.2.2. By Distribution Channel

19. Market Structure Analysis

    19.1. Market Analysis by Tier of Companies 

    19.2. Market Share Analysis of Top Players (%)

    19.3. Market Presence Analysis

        19.3.1. Regional Footprint of Players

        19.3.2. Route of Administration Footprint of Players

        19.3.3. Channel Footprint of Players

20. Competition Analysis

    20.1. Competition Dashboard

    20.2. Key Development Analysis

    20.3. Competition Benchmarking

    20.4. Competition Deep Dive 

        20.4.1. Biotest AG

            20.4.1.1. Overview

            20.4.1.2. Product Portfolio

            20.4.1.3. Key Financials

            20.4.1.4. Sales Footprint

            20.4.1.5. Strategy Overview

            20.4.1.6. Marketing Strategies

            20.4.1.7. Channel Strategies

        20.4.2. Baxter International Inc.

            20.4.2.1. Overview

            20.4.2.2. Product Portfolio

            20.4.2.3. Key Financials

            20.4.2.4. Sales Footprint

            20.4.2.5. Strategy Overview

            20.4.2.6. Marketing Strategies

            20.4.2.7. Channel Strategies

        20.4.3. Octapharma AG

            20.4.3.1. Overview

            20.4.3.2. Product Portfolio

            20.4.3.3. Key Financials

            20.4.3.4. Sales Footprint

            20.4.3.5. Strategy Overview

            20.4.3.6. Marketing Strategies

            20.4.3.7. Channel Strategies

        20.4.4. LFB Biotechnologies

            20.4.4.1. Overview

            20.4.4.2. Product Portfolio

            20.4.4.3. Key Financials

            20.4.4.4. Sales Footprint

            20.4.4.5. Strategy Overview

            20.4.4.6. Marketing Strategies

            20.4.4.7. Channel Strategies

        20.4.5. Grifols SA

            20.4.5.1. Overview

            20.4.5.2. Product Portfolio

            20.4.5.3. Key Financials

            20.4.5.4. Sales Footprint

            20.4.5.5. Strategy Overview

            20.4.5.6. Marketing Strategies

            20.4.5.7. Channel Strategies

        20.4.6. CSL Behring

            20.4.6.1. Overview

            20.4.6.2. Product Portfolio

            20.4.6.3. Key Financials

            20.4.6.4. Sales Footprint

            20.4.6.5. Strategy Overview

            20.4.6.6. Marketing Strategies

            20.4.6.7. Channel Strategies

        20.4.7. China Biologics Route of Administrations Inc.

            20.4.7.1. Overview

            20.4.7.2. Product Portfolio

            20.4.7.3. Key Financials

            20.4.7.4. Sales Footprint

            20.4.7.5. Strategy Overview

            20.4.7.6. Marketing Strategies

            20.4.7.7. Channel Strategies

        20.4.8. Kedrion Biopharma

            20.4.8.1. Overview

            20.4.8.2. Product Portfolio

            20.4.8.3. Key Financials

            20.4.8.4. Sales Footprint

            20.4.8.5. Strategy Overview

            20.4.8.6. Marketing Strategies

            20.4.8.7. Channel Strategies

        20.4.9. BDI Pharma Inc.

            20.4.9.1. Overview

            20.4.9.2. Product Portfolio

            20.4.9.3. Key Financials

            20.4.9.4. Sales Footprint

            20.4.9.5. Strategy Overview

            20.4.9.6. Marketing Strategies

            20.4.9.7. Channel Strategies

        20.4.10. Bayers

            20.4.10.1. Overview

            20.4.10.2. Product Portfolio

            20.4.10.3. Key Financials

            20.4.10.4. Sales Footprint

            20.4.10.5. Strategy Overview

            20.4.10.6. Marketing Strategies

            20.4.10.7. Channel Strategies

        20.4.11. Biotest AG

            20.4.11.1. Overview

            20.4.11.2. Product Portfolio

            20.4.11.3. Key Financials

            20.4.11.4. Sales Footprint

            20.4.11.5. Strategy Overview

            20.4.11.6. Marketing Strategies

            20.4.11.7. Channel Strategies

        20.4.12. Baxalta Incorporated

            20.4.12.1. Overview

            20.4.12.2. Product Portfolio

            20.4.12.3. Key Financials

            20.4.12.4. Sales Footprint

            20.4.12.5. Strategy Overview

            20.4.12.6. Marketing Strategies

            20.4.12.7. Channel Strategies

        20.4.13. Kedrion SPA

            20.4.13.1. Overview

            20.4.13.2. Product Portfolio

            20.4.13.3. Key Financials

            20.4.13.4. Sales Footprint

            20.4.13.5. Strategy Overview

            20.4.13.6. Marketing Strategies

            20.4.13.7. Channel Strategies

        20.4.14. Astrazeneca PLC.

            20.4.14.1. Overview

            20.4.14.2. Product Portfolio

            20.4.14.3. Key Financials

            20.4.14.4. Sales Footprint

            20.4.14.5. Strategy Overview

            20.4.14.6. Marketing Strategies

            20.4.14.7. Channel Strategies

        20.4.15. Omrix Biopharma.

            20.4.15.1. Overview

            20.4.15.2. Product Portfolio

            20.4.15.3. Key Financials

            20.4.15.4. Sales Footprint

            20.4.15.5. Strategy Overview

            20.4.15.6. Marketing Strategies

            20.4.15.7. Channel Strategies

        20.4.16. Sanofi

            20.4.16.1. Overview

            20.4.16.2. Product Portfolio

            20.4.16.3. Key Financials

            20.4.16.4. Sales Footprint

            20.4.16.5. Strategy Overview

            20.4.16.6. Marketing Strategies

            20.4.16.7. Channel Strategies

        20.4.17. Cangene corporation

            20.4.17.1. Overview

            20.4.17.2. Product Portfolio

            20.4.17.3. Key Financials

            20.4.17.4. Sales Footprint

            20.4.17.5. Strategy Overview

            20.4.17.6. Marketing Strategies

            20.4.17.7. Channel Strategies

21. Assumptions and Acronyms Used

22. Research Methodology

Recommendations

Healthcare

Antibody Therapy Market

March 2022

REP-GB-14362

February 2023

345 pages

Healthcare

Monoclonal Antibodies Market

November 2022

REP-GB-15756

286 pages

Healthcare

HIV Antivirals Market

June 2022

REP-GB-15095

300 pages

Explore Healthcare Insights

View Reports
Future Market Insights

Antiviral Immunoglobulin Market